ABPA Evaluation Work-Up
Begin the diagnostic evaluation by immediately ordering A. fumigatus-specific IgE; if ≥0.35 kUA·L⁻¹, proceed with serum total IgE measurement, and if ≥500 IU·mL⁻¹, complete the full diagnostic panel including A. fumigatus-specific IgG, peripheral blood eosinophil count, and thin-section chest CT. 1
Initial Screening Algorithm
The 2024 ISHAM-ABPA working group guidelines provide a clear stepwise approach 1:
Step 1: A. fumigatus-specific IgE
- Order this first in any patient with asthma, cystic fibrosis, COPD, or bronchiectasis who has clinical suspicion
- Clinical red flags include: expectoration of brownish mucus plugs, recurrent wheezing despite treatment, fleeting pulmonary infiltrates, or unexplained deterioration
Step 2: If A. fumigatus-specific IgE ≥0.35 kUA·L⁻¹
- Measure serum total IgE immediately
- This two-step approach prevents unnecessary testing in non-sensitized patients
Step 3: If serum total IgE ≥500 IU·mL⁻¹
- Complete the full diagnostic battery (detailed below)
Complete Diagnostic Panel
Once both essential components are positive, obtain 1:
Laboratory Tests
- A. fumigatus-specific IgG (using lateral flow assay or enzyme immunoassay)
- Use population-specific cut-offs when available (≥27 mgA·L⁻¹ for India, ≥60 for Japan, ≥40 for UK)
- Otherwise use manufacturer recommendations 1
- Peripheral blood eosinophil count (≥500 cells·μL⁻¹ diagnostic threshold)
- Historical values are acceptable 1
- Sputum fungal culture (suggested but not mandatory for ABPA; mandatory for ABPM) 1
Imaging Studies
- Thin-section chest CT (mandatory at baseline) 1
- Look specifically for: bronchiectasis, mucus plugging, high-attenuation mucus (HAM)
- HAM is pathognomonic—if present, confirms ABPA even without all other criteria 1
- Also assess for fleeting opacities, finger-in-glove appearance, lung collapse
- Chest radiograph may show fleeting opacities (high specificity for ABPA) 1
Pulmonary Function Tests
- Obtain baseline spirometry to characterize disease severity and establish monitoring parameters 1
Diagnostic Criteria Application
ABPA diagnosis requires 1:
Essential Components (both mandatory):
- A. fumigatus-specific IgE ≥0.35 kUA·L⁻¹
- Serum total IgE ≥500 IU·mL⁻¹
Plus any TWO of the following:
- Positive A. fumigatus-specific IgG
- Blood eosinophil count ≥500 cells·μL⁻¹
- Chest CT findings consistent with ABPA (bronchiectasis, mucus plugging, HAM) OR fleeting opacities on chest radiograph
Critical Caveats
Low total IgE exceptions 1:
- Serum total IgE <500 IU·mL⁻¹ may be acceptable if all other criteria are fulfilled
- This occurs with: prior glucocorticoid treatment, elderly patients, or constitutively low baseline IgE
Pathognomonic finding 1:
- High-attenuation mucus on CT confirms ABPA diagnosis even if other criteria are incomplete
When to consider ABPM instead 1:
- If A. fumigatus-specific IgE <0.35 kUA·L⁻¹ but clinical picture suggests allergic bronchopulmonary mycosis
- Requires: repeated isolation of non-Aspergillus fungi (≥2 sputum cultures or 1 BAL), fungus-specific IgE, total IgE ≥500 IU·mL⁻¹, plus two additional criteria
- Test for IgE against rAsp f1, f2, and f4—absence strongly supports ABPM over ABPA 1
Tests NOT Recommended
- Serum galactomannan: Do not use for ABPA diagnosis 1
- Routine bronchoscopy: Not recommended unless 1:
- Diagnosis remains uncertain after full workup
- Suspected ABPM with uninformative sputum cultures
- Unexplained hemoptysis
- Suspicion of concurrent mycobacterial infection before starting glucocorticoids
Alternative When Serology Unavailable
If Aspergillus-specific IgE testing is unavailable, a positive type 1 skin test to Aspergillus antigens is acceptable 1
This algorithmic approach ensures systematic evaluation while avoiding unnecessary testing, with the 2024 ISHAM guidelines representing the most current international consensus for ABPA diagnosis.